Effect of micafungin on cytochrome P450 3A4 and multidirug resistance protein 1 activities, and its comparison with azole antifungal drugs

Journal of Pharmacy and Pharmacology

Volumn 57, Issue 6, 2005, Pages 759-764

  Sakaeda, Toshiyuki ^a   Iwaki, Koichi ^a   Kakumoto, Mikio ^a   Nishikawa, Mika ^a   Niwa, Toshiro ^b   Jin, Jiang Shu ^a   Nakamura, Tsutomu ^a   Nishiguchi, Kohshi ^a   Okamura, Noboru ^c   Okumura, Katsuhiko ^a  

^a KOBE UNIVERSITY   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLOSPORIN; CYTOCHROME P450 3A4; DIGOXIN; FLUCONAZOLE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN 1; NELFINAVIR; NIFEDIPINE; NIFEDIPINE OXIDASE; OXIDOREDUCTASE; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; RITONAVIR; SAQUINAVIR; TACROLIMUS; TERBINAFINE; TRITIUM; UNCLASSIFIED DRUG; VORICONAZOLE;

ANIMAL CELL; ARTICLE; CELL STRAIN; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; LIVER MICROSOME; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN TRANSPORT;

ANIMALS; ANTIFUNGAL AGENTS; AZOLES; BIOLOGICAL TRANSPORT; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INHIBITORY CONCENTRATION 50; LIPOPROTEINS; MICROSOMES, LIVER; P-GLYCOPROTEIN; PEPTIDES, CYCLIC; SWINE;

EID: 21044439668     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357056118     Document Type: Article

References (47)

1. Ahonen, J., Olkkola, K. T., Neuvonen, P. J. (1997) Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur. J. Clin. Pharmacol. 51: 415-419
2. Ahonen, J., Olkkola, K. T., Takala, A., Neuvonen, P. J. (1999) Interaction between fluconazole and midazolam in intensive care patients. Acta Anaesthesiol. Scand. 43: 509-514
3. Back, D. J., Tjia, J. F. (1991) Comparative effects of the anti-mycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br. J. Clin. Pharmacol. 32: 624-626
4. Benet, L. Z., Cummins, C. L., Wu, C. Y. (2003) Transporterenzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr. Drug Metab. 4: 393-398
5. Colburn, D. E., Giles, F. J., Oladovich, D., Smith, J. A. (2004) In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology 9: 217-221
6. Denning, D. W. (2003) Echinocandin antifungal drugs. Lancet 262: 1142-1151
7. Fitzsimmons, M. E., Collins, J. M. (1997) Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4. Drug Metab. Dispos. 25: 256-266
8. Foradori, A., Mezzano, S., Videla, C., Pefaur, J., Elberg, A. (1998) Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazole in stable adult kidney transplants. Tansplant. Proc. 30: 1685-1687
9. Jarvis, B., Figgitt, D. P., Scott, L. J. (2004) Micafungin. Drugs 64: 969-984
10. Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J. J., Roden, D. M. (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101: 289-294
11. Koudriakova, T., Iatsimirskaia, E., Utkin, I., Gangl, E., Vouros, P., Storozhuk, E., Orza, D., Marinina J., Gerber, N. (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab. Dispos. 26: 552-561
12. Lee, C. G., Gottesman, M. M., Cardarelli, C. O., Ramachandra, M., Jeang, K. T., Ambudkar, S. V., Pastan, I., Dey, S. (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37: 3594-3601
13. Lin, J. H., Yamazaki, M. (2003) Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 42: 59-98
14. Marzolini, C., Paus, E., Buclin, T., Kim, R. B. (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75: 13-33
15. McLachlan, A. J., Tett, S. E. (1998) Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. Ther. Drug Monit. 20: 390-395
16. Moore, R. D., Chaisson, R. E. (1996) Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann. Intern. Med. 124: 633-642
17. Moreno, M., Latorre, A., Manzanares, E., Morales, E., Herrero, J. C., Dominguez-Gil, B., Carreno, A., Cubas, A., Delgado, M., Andres, A., Morales, J. M. (1999) Clinical management of tacrolimus drug interactions in renal transplant patients. Transplant. Proc. 31: 2252-2253
18. Nakasa, H., Nakamura, H., Ono, S., Tsutsui, M., Kiuchi, M., Ohmori, S., Kitada M. (1998) Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur. J. Clin. Pharmacol. 54: 177-183
19. Niwa, T., Shiraga, T., Yamasaki, S., Ishibashi, K., Ohno, Y., Kagayama, A. (2003) In vitro activation of 7-benzyloxyresorufin O-debenzylation and nifedipine oxidation in human liver microsomes. Xenobiotica 33: 717-729
20. Odds, F. C., Brown, A. J. P., Gow, N. A. R. (2003) Antifungal agents: mechanism of action. Trends Microbiol. 11: 272-279
21. Olkkola, K. T., Ahonen, J., Neuvonen, P. J. (1996) The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth. Analg. 82: 511-516
22. Perloff, M. D., Störmer, E., von Moltke, L. L., Greenblatt, D. J. (2003) Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm. Res. 20: 1177-1183
23. Ribaud, P., Chastang, C., Latge, J. P., Baffroy-Lafitte, L., Parquet, N., Devergie, A., Esperou, H., Selimi, F., Rocha, V., Esperou, H., Selimi, F., Rocha, V., Derouin, F., Socie, G., Gluckman, E. (1999) Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin. Infect. Dis. 28: 322-330
24. Sakaeda, T., Takara, K., Kakumoto, M., Ohmoto, N., Nakamura, T., Iwaki, K., Tanigawara, Y., Okumura, K. (2002) Simvastatin and lovastatin, but not pravastatin, interact with MDR1. J. Pharm. Pharmacol. 54:419-423
25. Sakaeda, T., Nakamura, T., Okumura, K. (2003) Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4: 397-410
26. Schinkel, A. H., Jonker, J. W. (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55: 3-29
27. Schwab, M., Eichelbaum, M., Fromm, M. F. (2003) Genetic polymorphisms of the human MDR1 drug transporter. Anna. Rev. Pharmacol. Toxicol. 43: 285-307
28. Sud, K., Singh, B., Krishna, V. S., Thennarasu, K., Kohli, H. S., Jha, V., Gupta, K. L., Sakhuja, V. (1999) Unpredictable cyclosporin-fluconazole interaction in renal transplant recipients. Nephrol. Dial. Transplant. 14: 1698-1703
29. Shader, R. I., von Moltke, L. L., Schmider, J., Harmatz, J. S., Greenblatt, D. J. (1996) The clinician and drug interactions - an update. J. Clin. Psychopharmacol 16: 197-201
30. Takara, K., Kakumoto, M., Tanigawara, Y., Funakoshi, J., Sakaeda, T., Okumura, K. (2002a) Interaction of digoxin with antihypertensive drugs via MDRl. Life Sci. 70: 1491-1500
31. 2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur. J. Pharm. Sci. 16: 159-165
32. 1). J. Pharmacol. Exp. Ther. 263: 840-845
33. Townsend, R., Herbert, M., Wisemandle, W., Bekersky, I. (2002a) Concomitant pharmacokinetics (PK) of micafungin, an echinocandin antifungal, and cyclosporine in healthy volunteers. J. Clin. Pharmacol. 42: 1054
34. Townsend, R., Hebert, M., Wisemandle, W., Bekersky, I. (2002b) Concomitant pharmacokinetics (PK) of micafungin, an echinocandin antifungal, and tacrolimus in healthy volunteers. J. Clin. Pharmacol. 42: 1055
35. Tran, T. H., von Moltke, L. L., Venkatakrishnan, K., Granda, B. W., Gibbs, M. A., Obach, R. S., Harmatz, J. S., Greenblatt, D. J. (2002) Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Melab. Dispos. 30: 1441-1445
36. Ueda, K., Okamura, N., Hirai, M., Tanigawara, Y., Saeki, T., Kioka, N., Komano, T., Hori, R. (1992) Human P-glycoprotein transports cortisol, aldosterone and dexamethasone, but not progesterone. J. Biol. Chem. 267: 24 248-24 252
37. Varhe, A., Olkkola, K. T., Neuvonen, P. J. (1996) Fluconazole, but not terbinafine, enchances the effects of triazolam by inhibiting its metabolism. Br. J. Clin. Pharmacol. 41: 319-323
38. Venkatakrishnan, K., von Moltke, L. L., Greenblatt, D. J. (2000) Effects of the antifungal agents on oxidative drug metabolism. Clin. Pharmacokinet. 38: 111-180
39. Venkataramanan, R., Zang, S., Gayowski, T., Singh, N. (2002) Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antmicrob. Agents Chemother. 46: 3091-3093
40. Vickers, A. E., Sinclair, J. R., Zollinger, M., Heitz, F., Glänzel, U., Johanson, L., Fischer, V. (1999) Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab. Dispos. 27: 1029-1038
41. von Moltke, L. L., Greenblatt, D. J., Schmider, J., Duan, S. X., Wright, C. E., Harmatz, J. S., Shader, R. I. (1996) Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluxetine, and by azole antifungal agents. J. Clin. Pharmacol. 36: 783-791
42. von Moltke, L. L., Granda, B. W., Grassi, J. M., Perloff, M. D., Vishnuvardhan, D. Greenblatt, D. J. (2004) Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice. Drug Metab. Dispos. 32: 800-804
43. Wacher, V. J., Wu, C.-Y., Benet, L. Z. (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13: 129-134
44. Wacher, V. J., Silverman, J. A., Zhang, Y., Benet, L. Z. (1998) Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87: 1322-1330
45. Wacher, V. J., Salphati, L., Benet, L. Z. (2001) Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev. 46: 89-102
46. Wandel, C., Kim, R. B., Kajiji, S., Guengerich, F. P., Wilkinson, G. R., Wood, A. J. J. (1999) P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res. 59: 3944-3948
47. Wexler, D., Courtney, R., Richards, W., Banfield, C., Lim, J., Laughlin, M. (2004) Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur. J. Pharm. Sci. 21: 645-653